Chemical Modification of siRNAs for In Vivo Use
MA Behlke - Oligonucleotides, 2008 - liebertpub.com
Well over a hundred reports have been published describing use of synthetic small-
interfering RNAs (siRNAs) in animals. The majority of these reports employed unmodified …
interfering RNAs (siRNAs) in animals. The majority of these reports employed unmodified …
Developments in liposomal drug delivery systems
N Maurer, DB Fenske, PR Cullis - Expert opinion on biological …, 2001 - Taylor & Francis
Liposomes are the leading drug delivery systems for the systemic (iv.) administration of
drugs. There are now liposomal formulations of conventional drugs that have received …
drugs. There are now liposomal formulations of conventional drugs that have received …
Identification of CpG oligonucleotide sequences with high induction of IFN‐α/β in plasmacytoid dendritic cells
A Krug, S Rothenfusser, V Hornung… - European journal of …, 2001 - Wiley Online Library
The immature plasmacytoid dendritic cell (PDC) is identical with the principal type I IFN‐
producing cell upon viral infection. Oligodeoxynucleotides which contain unmethylated CpG …
producing cell upon viral infection. Oligodeoxynucleotides which contain unmethylated CpG …
Antisense therapy for cancer—the time of truth
B Jansen, U Zangemeister-Wittke - The lancet oncology, 2002 - thelancet.com
The recent acceleration in the identification and characterisation of new molecular targets for
cancer and the limited effectiveness of conventional treatment strategies has focused …
cancer and the limited effectiveness of conventional treatment strategies has focused …
Methods for enhancing antibody-induced cell lysis and treating cancer
G Weiner, G Hartmann - US Patent 7,534,772, 2009 - Google Patents
US7534772B2 - Methods for enhancing antibody-induced cell lysis and treating cancer -
Google Patents US7534772B2 - Methods for enhancing antibody-induced cell lysis and …
Google Patents US7534772B2 - Methods for enhancing antibody-induced cell lysis and …
Cationic liposomes as vaccine adjuvants
D Christensen, KS Korsholm, I Rosenkrands… - Expert review of …, 2007 - Taylor & Francis
Cationic liposomes are lipid-bilayer vesicles with a positive surface charge that have re-
emerged as a promising new adjuvant technology. Although there is some evidence that …
emerged as a promising new adjuvant technology. Although there is some evidence that …
Tissue engineering via local gene delivery:: Update and future prospects for enhancing the technology
J Bonadio - Advanced drug delivery reviews, 2000 - Elsevier
This review describes the status of a local plasmid-based gene transfer technology known
as the gene activated matrix (GAM). Studies over the past 6 years suggest that GAM may …
as the gene activated matrix (GAM). Studies over the past 6 years suggest that GAM may …
Immunostimulatory nucleic acids for the treatment of asthma and allergy
RL Bratzler, DM Petersen, Y Fouron - US Patent 7,585,847, 2009 - Google Patents
2001-12-26 Assigned to COLEY PHARMACEUTICAL GROUP, INC. reassignment COLEY
PHARMACEUTICAL GROUP, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE …
PHARMACEUTICAL GROUP, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE …
CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens
B Jahrsdörfer, G Hartmann, E Racila… - Journal of leukocyte …, 2001 - academic.oup.com
Multiple factors, including expression of costimulatory molecules, antigen-presenting
molecules, and target antigens, likely impact the efficacy of antibody therapy and other …
molecules, and target antigens, likely impact the efficacy of antibody therapy and other …
Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate …
H Weighardt, C Feterowski, M Veit, M Rump… - The Journal of …, 2000 - journals.aai.org
Recent reports support the concept that the major defect in polymicrobial sepsis is an
impaired immunologic response to infection. Oligodeoxynucleotides containing CpG …
impaired immunologic response to infection. Oligodeoxynucleotides containing CpG …